Publication | Closed Access

2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)

Bone DiseaseZoledronic AcidBone LossBreast OncologyMedicinePharmacologyClinical TrialsBreast CancerPharmacotherapyAromataseOncologyRadiation OncologyOsteoporosisE-zo-fast TrialHealth Sciences